Aurinia Pharmaceuticals Valuation
| AUPH Stock | USD 5.03 0.06 1.18% |
At this time, the firm appears to be fairly valued. Aurinia Pharmaceuticals shows a prevailing Real Value of $4.9 per share. The current price of the firm is $5.03. Our model approximates the value of Aurinia Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 483.34 M, profit margin of (0.44) %, and Return On Equity of -0.2 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and trading away overvalued instruments since, at some point, asset prices and their ongoing real values will blend. Key fundamental drivers impacting Aurinia Pharmaceuticals' valuation include:
Price Book 1.9514 | Enterprise Value 483.3 M | Enterprise Value Ebitda (7.69) | Price Sales 4.2023 | Forward PE 128.2051 |
Fairly Valued
Today
Please note that Aurinia Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of Aurinia Pharmaceuticals is based on 3 months time horizon. Increasing Aurinia Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Aurinia Pharmaceuticals is useful when determining the fair value of the Aurinia stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Aurinia Pharmaceuticals. Since Aurinia Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aurinia Stock. However, Aurinia Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.03 | Real 4.9 | Target 14.0 | Hype 5.09 | Naive 5.28 |
The real value of Aurinia Stock, also known as its intrinsic value, is the underlying worth of Aurinia Pharmaceuticals Company, which is reflected in its stock price. It is based on Aurinia Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Aurinia Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aurinia Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aurinia Pharmaceuticals helps investors to forecast how Aurinia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aurinia Pharmaceuticals more accurately as focusing exclusively on Aurinia Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Aurinia Pharmaceuticals' intrinsic value based on its ongoing forecasts of Aurinia Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Aurinia Pharmaceuticals' closest peers. When choosing an evaluation method for Aurinia Pharmaceuticals, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Aurinia Pharmaceuticals Investments |
|
Aurinia Valuation Drivers Correlation
Many accounts on the financial statements of Aurinia Pharmaceuticals are highly interrelated and sometimes correlated. Consequently, when conducting Aurinia's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Aurinia
Click cells to compare fundamentals
Aurinia Valuation Trend
Knowing Aurinia Pharmaceuticals' actual value is paramount for traders to make sound investment determinations. Aurinia Pharmaceuticals' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Aurinia Pharmaceuticals' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Aurinia Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Aurinia Market Cap
Aurinia Pharmaceuticals is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is presently estimated at about 56.2 Billion. Aurinia Pharmaceuticals claims roughly 739.72 Million in market capitalization contributing just under 2% to equities under Health Care industry.Aurinia Pharmaceuticals Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Aurinia Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aurinia Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aurinia Pharmaceuticals competition to find correlations between indicators driving Aurinia Pharmaceuticals's intrinsic value. More Info.Aurinia Pharmaceuticals is rated below average in price to earning category among related companies. It is rated below average in price to book category among related companies . The Aurinia Pharmaceuticals' current Price To Book Ratio is estimated to increase to 3.58. Comparative valuation analysis is a catch-all model that can be used if you cannot value Aurinia Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aurinia Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aurinia Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Aurinia Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Aurinia Pharmaceuticals and how it compares across the competition.
About Aurinia Pharmaceuticals Valuation
The stock valuation mechanism determines the current worth of Aurinia Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Aurinia Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Aurinia Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Aurinia Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Aurinia Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aurinia Pharmaceuticals. We calculate exposure to Aurinia Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aurinia Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 161.4 M | 169.4 M | |
| Pretax Profit Margin | (0.44) | (0.46) | |
| Operating Profit Margin | (0.47) | (0.50) | |
| Net Loss | (0.44) | (0.47) | |
| Gross Profit Margin | 0.92 | 0.97 |
8 Steps to conduct Aurinia Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Aurinia Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Aurinia Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Aurinia Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Aurinia Pharmaceuticals' revenue streams: Identify Aurinia Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Aurinia Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Aurinia Pharmaceuticals' growth potential: Evaluate Aurinia Pharmaceuticals' management, business model, and growth potential.
- Determine Aurinia Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Aurinia Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Aurinia Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Aurinia Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 143.2 M | |
| Forward Price Earnings | 128.2051 |
Aurinia Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Aurinia Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Aurinia we look at many different elements of the entity such as Aurinia's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Aurinia Pharmaceuticals' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Aurinia Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aurinia Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aurinia Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aurinia Pharmaceuticals' worth.When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Aurinia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.225 | Quarterly Revenue Growth 0.586 | Return On Assets (0.11) | Return On Equity (0.20) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.